Company History
Company History
2023
- DEC Awarded 20th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
- JUL Achieved 2nd Place in the BioAsia 2023 National Science Council “New Business Incubation Exhibition Selection”
- MAY Awarded 2023 NBRP DEMODAY – Investor’s Choice Award (EF-001: Cerebraca® Wafer – GBM)
- APR Taipei Headquters established
2022
- DEC Awarded 19th National Innovation Award – Clinical innovation (EF-001: Cerebraca® Wafer – GBM)
2021
- DEC
- Awarded 18th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
- Awarded 18th National Innovation Award – Excelsior Award (HK-001: ALS)
- Awarded 18th National Innovation Award (EF-009: EF-009 Wafer – Pancreatic Cancer)
2020
- DEC Awarded 17th National Innovation Award (EF-011: Pulmonary fibrosis)
- JAN IND application approved by TFDA (EF-009: EF-009 Wafer – Pancreatic Cancer)
2019
- DEC
- Awarded 16th National Innovation Award – Excelsior Award (EF-001: Cerebraca® Wafer – GBM)
- Awarded 16th National Innovation Award – Excelsior Award (HK-001: ALS)
- Awarded 16th National Innovation Award (EF-012: Immunomodulatory therapy for cancer)
- OCT
- IND application approved by USFDA (EF-009: EF-009 Wafer – Pancreatic Cancer)
- Congress of Neurological Surgeons – selected late-breaking presentation with the highest score (EF-001: Cerebraca® Wafer – GBM)
- JUL Taipei Biotech Awards – Innovation Award (EF-001: Cerebraca® Wafer – GBM)
- FEB IND application approved by TFDA (HK-001: ALS)
2018
- FEB IND application approved by USFDA (HK-001: ALS)
2017
- NOV Awarded 14th National Innovation Award (HK-001: ALS)
- SEP Received funding from the Ministry of Economic Affairs’ Fast Track Program (EF-001: Cerebraca® Wafer – GBM)
2016
- NOV IND application approved by TFDA (EF-001: Cerebraca® Wafer – GBM)
- AUG IND application approved by USFDA (EF-001: Cerebraca® Wafer – GBM)
- JAN Everfront Biotech Inc. is qualified by the qualified for governmental incentives under Biotech and New Pharmaceutical Development Act in Taiwan
2015
- AUG Orphan drug Designation Granted by USFDA (EF-001: Cerebraca® Wafer – GBM)
2014
- DEC
- Awarded 11th National Innovation Award (EF-001: Cerebraca® Wafer – GBM)
- Received funding support from the A+ Enterprise Innovation R&D Program of the Ministry of Economic Affairs (HK-001: ALS)
2013
- MAY Received funding from the Ministry of Economic Affairs for the Science and Technology Development Program (EF-001: Cerebraca® Wafer – GBM)
2010
- DEC Everfront Biotech Inc. was formally established by President Ho-Ching Chen, with Dr. Chou Pei-Wen serving as Chairman and General Manager. Dr. Shinn-Zong Lin, Dr. Horng-Jyh Harn, and Dr. Tzyy-Wen Chiou were invited to join the scientific advisory board, and Dr. Tza-Zen Chuang was appointed to the consulting advisory team
